Viscient Biosciences is a San Diego-based biotechnology company working at the intersection of human 3D tissue technology and multi-omics (genomics, transcriptomics, metabolomics) analysis to discover and develop drugs across a range of therapeutic areas with significant unmet medical need. For NAFLD/NASH, we have modeled disease progression in vitro, identified novel disease-driver gene targets, and are advancing medicinal chemistry to develop drugs that modulate these targets. For COVID-19, Viscient is creating a 3D bioprinted lung tissue to test potential COVID-19 therapies to accelerate development.